Simplex Group Earns BusinessRate Recognition and National Media Mention Among Top DOT Compliance Companies in the U.S.
Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial ...
Replimune (REPL) stock plunged 19% after FDA rejected RP1 melanoma treatment for the second time, citing trial design issues.
The second time is not the charm for Replimune’s melanoma candidate RP1. | The second time is not the charm for Replimune’s ...
Replimune Group, Inc. stock drops after a second FDA rejection for RP1 melanoma; cash runway <12 months. Click for more on ...
Opinion
16hOpinion
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced ...
New evidence links viral infections to dementia risk, suggesting vaccines and antiviral therapies may offer preventive ...
Patients received an initial intratumoral injection of RP1 with up to 7 additional doses every 2 weeks, plus 240 mg nivolumab ...
SHELTON, CT / ACCESS Newswire / April 7, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...
A CORONER has sounded the alarm over epilepsy drug shortages after a man died unable to quickly access vital medication. Paul ...
Revenues of €1.8 billion (-4% versus PY) driven by solid performance across key therapeutic areas and global markets, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results